David Baudry
Overview
Explore the profile of David Baudry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
314
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dand N, Stuart P, Bowes J, Ellinghaus D, Nititham J, Saklatvala J, et al.
Nat Commun
. 2025 Feb;
16(1):2051.
PMID: 40021644
Psoriasis is a common, debilitating immune-mediated skin disease. Genetic studies have identified biological mechanisms of psoriasis risk, including those targeted by effective therapies. However, the genetic liability to psoriasis is...
2.
Schwarz C, Blegvad C, Baudry D, Tosi I, Lee S, Chung R, et al.
J Invest Dermatol
. 2025 Feb;
PMID: 39983980
No abstract available.
3.
Thomas C, Baudry D, Arkir Z, Coker B, Dasandi T, Powell K, et al.
J Invest Dermatol
. 2025 Feb;
PMID: 39983977
An increasing number of individuals receiving psoriasis biologics achieve clear/nearly clear skin (disease control). Clinical trial data indicate that some maintain disease control with lower doses, especially those with higher...
4.
Dand N, Stuart P, Bowes J, Ellinghaus D, Nititham J, Saklatvala J, et al.
medRxiv
. 2023 Oct;
PMID: 37873414
Psoriasis is a common, debilitating immune-mediated skin disease. Genetic studies have identified biological mechanisms of psoriasis risk, including those targeted by effective therapies. However, the genetic liability to psoriasis is...
5.
Tsakok T, Saklatvala J, Rispens T, Loeff F, de Vries A, Allen M, et al.
JCI Insight
. 2023 Feb;
8(4).
PMID: 36810251
Targeted biologic therapies can elicit an undesirable host immune response characterized by the development of antidrug antibodies (ADA), an important cause of treatment failure. The most widely used biologic across...
6.
Mahil S, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown M, et al.
Lancet Rheumatol
. 2021 Nov;
4(1):e42-e52.
PMID: 34778846
Background: COVID-19 vaccines have robust immunogenicity in the general population. However, data for individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains scarce. Our previously published cohort study showed...
7.
Douroudis K, Ramessur R, Barbosa I, Baudry D, Duckworth M, Angit C, et al.
J Invest Dermatol
. 2021 Nov;
142(6):1617-1628.e10.
PMID: 34767815
The identification of robust endotypes-disease subgroups of clinical relevance-is fundamental to stratified medicine. We hypothesized that HLA-C∗06:02 status, the major genetic determinant of psoriasis, defines a psoriasis endotype of clinical...
8.
Mahil S, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown M, et al.
Lancet Rheumatol
. 2021 Jul;
3(9):e627-e637.
PMID: 34258590
Background: Patients on therapeutic immunosuppressants for immune-mediated inflammatory diseases were excluded from COVID-19 vaccine trials. We therefore aimed to evaluate humoral and cellular immune responses to COVID-19 vaccine BNT162b2 (Pfizer-BioNTech)...
9.
Loeff F, Tsakok T, Dijk L, Hart M, Duckworth M, Baudry D, et al.
J Invest Dermatol
. 2020 Apr;
140(11):2129-2137.
PMID: 32283057
Ustekinumab is an effective treatment for psoriasis, but response varies between patients. The formation of anti-drug antibodies (ADAs) may explain part of this variation by reducing the free ustekinumab level....
10.
Pan S, Tsakok T, Dand N, Lonsdale D, Loeff F, Bloem K, et al.
Clin Transl Sci
. 2020 Jan;
13(2):400-409.
PMID: 31995663
Variation in response to biologic therapy for inflammatory diseases, such as psoriasis, is partly driven by variation in drug exposure. Real-world psoriasis data were used to develop a pharmacokinetic/pharmacodynamic (PK/PD)...